Retinal vascular disease and the pathogenesis of facioscapulohumeral muscular dystrophy. A signalling message from Wnt?

Neuromuscular Disorders

Volumn 21, Issue 4, 2011, Pages 263-271

  Fitzsimons, Robin B ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Coats Disease; Facioscapulohumeral muscular dystrophy; Myogenesis; Retina; Satellite cell; Telangiectasis; Wnt

Indexed keywords

COHESIN; GENE PRODUCT; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MEMBRANE PROTEIN; MYOD PROTEIN; MYOGENIC FACTOR 5; MYOGENIN; NORRIN; PROTEIN TSPAN12; T CELL FACTOR PROTEIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR PAX3; UNCLASSIFIED DRUG; WNT PROTEIN; WNT1 PROTEIN; WNT3A PROTEIN; WNT5A PROTEIN;

ANGIOGENESIS; ARTICLE; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; DEVELOPMENTAL DISORDER; DISEASE ASSOCIATION; EMBRYO DEVELOPMENT; EXUDATIVE RETINITIS; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; MOLECULAR PATHOLOGY; MUSCLE DEVELOPMENT; MUSCLE REGENERATION; MYOBLAST; NORRIE DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RETINA DISEASE; RETINA VASCULAR DISEASE; SATELLITE CELL; SIGNAL TRANSDUCTION; TELOMERE; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; X CHROMOSOME LINKED DISORDER;

CELL CYCLE PROTEINS; CHROMOSOMAL PROTEINS, NON-HISTONE; HUMANS; MUSCLE DEVELOPMENT; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; NEOVASCULARIZATION, PHYSIOLOGIC; RETINAL VASCULITIS; RETINAL VESSELS; SATELLITE CELLS, SKELETAL MUSCLE; SIGNAL TRANSDUCTION; TELOMERASE; TRANSCRIPTION FACTORS; WNT PROTEINS;

EID: 79952736706     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2011.02.002     Document Type: Article

References (121)

1. Wijmenga C., Frants R.R., Brouwer O.F., Moerer P., Weber J.L., Padberg G.W. Location of facioscapulohumeral muscular dystrophy gene on chromosome 4. Lancet 1990, 336:651-653.
2. van Deutekom J.C., Wijmenga C., van Tienhoven E.A., et al. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet 1993, 2:2037-2042.
3. Bengtsson U., Altherr M.R., Wasmuth J.J., Winokur S.T. High resolution fluorescence in situ hybridization to linearly extended DNA visually maps a tandem repeat associated with facioscauplohumeral muscular dystrophy immediately adjacent to the telomere of 4q. Hum Mol Genet 1994, 3:1801-1805.
4. De Greef J.C., Lemmers R.J., van Engelen B.G., et al. Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum Mut 2009, 30:1449-1459.
5. Lemmers R.J., Wohlgemuth M., van der Gaag K.J., et al. Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy. Am J Hum Genet 2007, 81:884-894.
6. Gabriels J., Beckers M.C., Ding H., et al. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3kb element. Gene 1999, 236:25-32.
7. Dixit M., Ansseau E., Tassin A., et al. DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc Natl Acad Sci USA 2007, 104:18157-18162.
8. Kowaljow V., Marcowycz A., Ansseau E., et al. The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Neuromuscul Disord 2007, 17:611-623.
9. Snider L., Geng L.N., Lemmers R.J.L.F., et al. Facioscapulohumeral muscular dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet 2010, 6:1-14. e1001181.
10. Lemmers R.J.L.F., van der Vliet P.J., Klooster R., et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 2010, 329:1650-1653.
11. Small R.G. Coats' disease and muscular dystrophy. Trans Am Acad Ophthalmol Otolaryngol 1968, 72:225-231.
12. Wulff J.D., Lin J.T., Kepes J.J. Inflammatory facioscapulohumeral muscular dystrophy and Coats syndrome. Ann Neurol 1982, 12:398-401.
13. Taylor D.A., Carroll J.E., Smith M.E., Johnson M.O., Johnston G.P., Brooke M.H. Facioscapulohumeral dystrophy associated with hearing loss and Coats syndrome. Ann Neurol 1982, 12:395-398.
14. Gurwin E.B., Fitzsimons R.B., Sehmi K.S., Bird A.C. Retinal telangiectasis in facioscapulohumeral muscular dystrophy with deafness. Arch Ophthalmol 1985, 103:1695-1700.
15. Fitzsimons R.B., Gurwin E.B., Bird A.C. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy. A general association with genetic and therapeutic implications. Brain 1987, 110:631-648.
16. Pauleikhoff D., Bornfield N., Bird A.C., Wessing A. Severe visual loss associated with retinal telangiectasis and facioscapulohumeral muscular dystrophy. Graefe's Arch Clin Exp Ophthalmol 1992, 230:362-365.
17. Coats G. Forms of retinal disease with massive exudation. Roy Lond Ophth Hospital Rep 1908, 525:440-525.
18. Reese A.B. Telangiectasis of the retina and Coats' Disease. Am J Ophthalmol 1956, 42:1-8.
19. Tarkkanen A., Laatikainen L. Coats's disease: clinical, angiographic, histopathological findings and clinical management. Br J Ophthalmol 1983, 67:766-776.
20. Black G.C., Perveen R., Bonshek R., et al. Coats' disease of the retina (unilateral retinal telangiectasis) caused by somatic mutation in the NDP gene: a role for norrin in retinal angiogenesis. Hum Mol Genet 1999, 8:2031-2035.
21. Voit T., Lamprecht A., Lenard H.G., Goebel H.H. Hearing loss in facioscapulohumeral dystrophy. Eur J Pediatr 1986, 145:280-285.
22. Padberg G.W., Brouwer O.F., de Keizer R.J., et al. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. Muscle Nerve 1995, (Suppl 2):S73-S80.
23. Ye X., Wang Y., Cahill H. E al. Norrin, frizzled-4, and Lrp5 signaling in endothelial cells controls a genetic program for retinal vascularization. Cell 2009, 139:285-298.
24. Clevers H. Eyeing up new Wnt pathway players. Cell 2009, 139:227-229.
25. Lin P., Shankar S.P., Duncan J., Slavotinek A., Stone E.M., Rutar T. Retinal vascular abnormalities and dragged maculae in a carrier with a new NDP mutation (c.268delC) that caused severe Norrie disease in the proband. J AAPOS 2010, 14:93-96.
26. Dickinson J.L., Sale M.M., Passmore A., et al. Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity. Clin Experiment Ophthalmal 2006, 34:682-688.
27. Warden S.M., Andreoli C.M., Mukai S. The Wnt signaling pathway in familial exudative vitreoretinopathy and Norrie Disease. Semin Ophthalmol 2007, 22:211-217.
28. Qin M., Hayashi H., Oshima K., Tahira T., Hayashi K., Kondo H. Complexity of the genotype-phenotype correlation in familial exudative vitreoretinopathy with mutations in the LRP5 and/or FZD4 genes. Hum Mutat 2005, 26:104-112.
29. Jiao X., Ventruto V., Trese M.T., Shastry B.S., Hejtmancik J.F. Autosomal recessive familial exudative vitreoretinopathy is associated with mutations in LRP5. Am J Hum Genet 2004, 75:878-884.
30. Chen Z.Y., Battinelli E.M., Fielder A., et al. A mutation in the Norrie disease gene (NDP) associated with X-linked familial exudative vitreoretinopathy. Nat Genet 1993, 5:180-183.
31. Chung B.-D., Kayserili H., Ai M., et al. A mutation in the signal sequence of LRP5 in a family with an osteoporosis-pseudoglioma syndrome (OPPG)-like phenotype indicates a novel disease mechanism for trinucleotide repeats. Hum Mut 2009, 30:641-648.
32. Xu Q., Wang Y., Dabdoub A., et al. Vascular development in the retina and inner ear. Control by norrin and frizzled-4, a high-affinity ligand-receptor pair. Cell 2004, 116:883-895.
33. Rehm H.L., Zhang D.-S., Brown M.C., et al. Vascular defects and sensorineural deafness in a mouse model of Norrie Disease. J Neurosci 2002, 22:4286-4292.
34. Rijsewijk F., Schuermann M., Wagenaar E., Parren P., Weigel D., Nusse R. The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell 1987, 50:649-657.
35. Logan C.Y., Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004, 20:781-810.
36. Van Amerongen R., Nusse R. Towards an integrated view of Wnt signaling in development. Development 2009, 136:3205-3214.
37. Winokur S.T., Chen Y.W., Masny P.S., et al. Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation. Hum Mol Genet 2003, 12:2895-2907.
38. Bosnakovski D., Xu Z., Gang E.J., et al. An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. EMBO J 2008, 27:2766-2779.
39. Penchaszadeh V. Facioscapulohumeral muscular dystrophy with congenital absence of sternocleinomastoid muscles. Birth Defects 1971, 7:116-117.
40. Cossu G., Borello U. Wnt signaling and the activation of myogenesis in mammals. EMBO J 1999, 18:6867-6872.
41. Borello U., Berarducci B., Murphy P., et al. The Wnt/beta-catenin pathway regulates Gli-mediated Myf5 expression during somitogenesis. Development 2006, 133:3723-3732.
42. Kim C.H., Neiswender H., Baik E.J., Xiong W.C., Mei L. Beta-catenin interacts with MyoD and regulates its transcription activity. Mol Cell Biol 2008, 28:2941-2951.
43. Tajbakhsh S., Borello U., Vivarelli E., et al. Differential activation of Myf5 and MyoD by different Wnts in explants of mouse paraxial mesoderm and the later activation of myogenesis in the absence of Myf5. Development 1998, 125:4155-4162.
44. Ikeya M., Takada S. Wnt signaling from the dorsal neural tube is required for the formation of the medial dermomyotome. Development 1998, 125:4969-4976.
45. Ridgeway A.G., Petropoulos H., Wilton S., Skerjane I.S. Wnt signaling regulates the function of MyoD and myogenin. J Biol Chem 2000, 275:32398-32405.
46. Hutcheson D.A., Zhao J., Merrell A., Haldar M., Kardon G. Embryonic and fetal limb myogenic cells are derived from developmentally distinct progenitors and have different requirements for beta-catenin. Genes Dev 2009, 23:997-1013.
47. Miller K.A., Barrow J., Collinson J.M., et al. A highly conserved Wnt-dependent TCF4 binding site within the proximal enhancer of the anti-myogenic Msx1 gene supports expression within Pax3-expressing limb bud muscle precursor cells. Dev Biol 2007, 311:665-678.
48. Descamps S., Arzouk H., Bacou F., et al. Inhibition of myoblast differentiation by Sfrp1 and Sfrp2. Cell Rissue Res 2008, 332:299-306.
49. Otto A., Schmidt C., Luke G., et al. Canonical Wnt signalling induces satellite-cell proliferation during adult skeletal muscle regeneration. J Cell Sci 2008, 121:2939-2950.
50. Le Grand F., Jones A.E., Seale V., Scime A., Rudnicki M.A. Wnt7a activates the planar cell polarity pathway to drive the symmetric expansion of satellite stem cells. Cell Stem Cell 2009, 4:535-547.
51. Perez-Ruiz A., Ono Y., Gnocchi V.F., Zammit P.S. Beta-Catenin promotes self-renewal of skeletal-muscle satellite cells. J Cell Sci 2008, 121:1373-1382.
52. Lepper C., Conway S.J., Fan C.M. Adult satellite cells and embryonic muscle progenitors have distinct genetic requirements. Nature 2009, 460:627-631.
53. Morosetti R., Mirabella M., Gliubizzi C., et al. Isolation and characterization of mesangioblasts from facioscapulohumeral muscular dystrophy muscle biopsies. Stem Cells 2007, 25:3173-3182.
54. Polesskaya A., Seale P., Rudnicki M.A. Wnt signaling induces the myogenic specification of resident CD45+ adult stem cells during muscle regeneration. Cell 2003, 113:841-852.
55. Shang Y.C., Wang S.H., Xiong F., et al. Wnt3a signaling promotes proliferation, myogenic differentiation, and migration of rat bone marrow mesenchymal stem cells. Acta Pharmacol Sin 2007, 28:1761-1774.
56. Fitzsimons R.B. Retinal vascular abnormalities in FSHD: a therapeutic message; clues to pathogenesis. FSHD Facioscapulohumeral Muscular Dystrophy: clinical medicine and molecular cell biology 2004, Garland BIOS Publishers Limited, Abingdon, p. 185-95. M. Upadhyaya, D.N. Cooper (Eds.).
57. Fitzsimons R.B. Facioscapulohumeral muscular dystrophy (FSHD). Do the retinal associations signify a signalling pathway disorder? (abstract). J Neurol Sci 2005, 238(Suppl. 1):S162.
58. Brack A.S., Conboy I.M., Conboy M.J., Shen J., Rando T.A. A temporal switch from notch to Wnt signaling in muscle stem cells is necessary for normal adult myogenesis. Cell Stem Cell 2008, 2:50-59.
59. Borycki A.G., Brunk B., Tajbakhsh S., Buckingham M., Chiang C., Emerson C.P. Sonic hedgehog controls epaxial muscle determination through Myf5 activation. Development 1999, 126:4053-4063.
60. Junge H.J., Yang S., Burton J.B., et al. TSPAN12 regulates retinal vascular development by promoting Norrin- but not Wnt-induced FZD4/beta-catenin signaling. Cell 2009, 139:299-311.
61. Poulter J.A., Ali M., Gilmour D.F., et al. Mutations in TSPAN12 cause autosomal-dominant familial exudative vitreoretinopathy. Am J Hum Genet 2010, 86:248-253.
62. Nikopoulos K., Gilissen C., Hoischen A., et al. Next-generation sequencing of a 40Mb linkage interval reveals TSPAN12 mutations in patients with familial exudative vitreoretinopathy. Am J Hum Genet 2010, 86:240-247.
63. Stenman J.M., Rajagopal J., Carroll T.J., Ishibashi M., McMahon J., McMahon A.P. Canonical Wnt signaling regulates organ-specific assembly and differentiation of CNS vasculature. Science 2008, 322:1247-1250.
64. Pourquie O. The segmentation clock: converting embryonic time into spatial pattern. Science 2003, 301:328-330.
65. Provis J.M., Leech J., Diaz C.M., Penfold P.L., Stone J., Keshet E. Development of the human retinal vasculature: cellular relations and VEGF expression. Exp Eye Res 1997, 65:555-568.
66. Nilausen K. The vasoformative tissue in the foetal retina with particular reference to the histochemical demonstration of its alkaline phosphatase activity. Acta Ophthalmol (Copenh) 1958, 36:65-70.
67. Michaelson I.C. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthal Soc UK 1948, 68:137-181.
68. Cogan D.G. Development and senescence of the human retinal vasculature. Trans Ophthalmol Soc UK 1963, 83:465-489.
69. Seitz R., Hackl S., Seibuchner T., Tamm E.R., Ohlmann A. Norrin mediates neuroprotective effects on retinal ganglion cells via activation of the Wnt/beta-catenin signalling pathway and the induction of neuroprotective growth factors in Muller cells. J Neurosci 2010, 30:5998-6010.
70. Patten B.M. Human embryology 1953, The Blakiston Company Inc., New York, Figs. 189-92 and p. 308-12. 2nd ed.
71. Padberg G.W., Lunt P.W., Koch M., Fardeau M. Workshop report. Diagnostic criteria for facioscapulohumeral muscular dystrophy. Neuromuscul Disord 1991, 1:231-234.
72. Yamanaka G., Goto K., Matsumara T., et al. Tongue atrophy in facioscapulohumeral muscular dystrophy. Neurology 2001, 57:733-735.
73. O'Rahilly R., Muller F. The early development of the hypoglossal nerve and occipital somites in staged human embryos. Am J Anat 1984, 169:237-257.
74. Mackenzie S., Walsh F.S., Graham A. Migration of hypoglossal myoblast precursors. Dev Dyn 1998, 213:349-358.
75. Wohlgemuth M., de Swart B.J., Kalf J.G., Joosten F.B., van der Vliet A.M., Padberg G.W. Dysphagia in facioscapulohumeral muscular dystrophy. Neurology 2006, 66:1926-1928.
76. Grifone R., Kelly R.G. Heartening news for head muscle development. Trends Genet 2007, 23:365-369.
77. Harel I., Nathan E., Tirosh-Finkel L., et al. Distinct origins and genetic programs of head muscle satellite cells. Dev Cell 2009, 16:822-832.
78. Mootoosamy R.C., Dietrich S. Distinct regulatory cascades for head and trunk myogenesis. Development 2002, 129:573-583.
79. Sambasivan R., Gayraud-Morel B., Dumas G.S., et al. Distinct regulatory cascades govern extraocular and pharyngeal arch muscle progenitor cell fates. Dev Cell 2009, 16:810-821.
80. Shih H.P., Gross M.K., Kioussi C. Muscle development: forming the head and trunk muscles. Acta histochem 2008, 110:97-108.
81. Lu J.-R., Bassel-Duby R., Hawkins A., et al. Control of facial muscle development by MyoR and capsulin. Science 2002, 298:2378-2381.
82. Prunotto C., Crepaldi T., Forni P.E., et al. Analysis of Mlc-lacZ Met mutants highlights the essential function of Met for migratory precursors of hypaxial muscles and reveals a role for Met in the development of hyoid arch-derived facial muscles. Dev Dyn 2004, 231:582-591.
83. Dietrich S., Schubert F.R., Healy C., Sharpe P.T., Lumsden A. Specification of the hypaxial musculature. Development 1998, 125:2235-2249.
84. Gensch N., Borchardt T., Schneider A., Riethmacher D., Braun T. Different autonomous myogenic cell populations revealed by ablation of Myf5-expressing cells during mouse embryogenesis. Development 2008, 135:1597-1604.
85. Kablar B., Krastel K., Ying C., Asakura A., Tapscott S.J., Rudnicki M.A. MyoD and Myf-5 differentially regulate the development of limb versus trunk skeletal muscle. Development 1997, 124:4729-4738.
86. Houzelstein D., Auda-Boucher G., Cheraud Y., et al. The homeobox gene Msx1 is expressed in a subset of somites, and in muscle progenitor cells migrating into the forelimb. Development 1999, 126:2689-2701.
87. Burke A.C., Nelson C.E., Morgan B.A., Tabin C. Hox genes and the evolution of vertebrate axial morphology. Development 1995, 121:333-346.
88. Bajard L., Relaix F., Lagha M., Rocancourt D., Daubas P., Buckingham M.E. A novel genetic hierarchy functions during hypaxial myogenesis: Pax3 directly activates Myf5 in muscle progenitor cells in the limb. Genes Dev 2006, 20:2450-2464.
89. Haldar M., Karan G., Tvrdik P., Capecchi M.R. Two cell lineages, myf5 and myf5-independent, participate in mouse skeletal myogenesis. Dev Cell 2009, 14:437-445.
90. Hadchouel J., Carvajal J.J., Daubas P., et al. Analysis of a key regulatory region upstream of the Myf5 gene reveals multiple phases of myogenesis, orchestrated at each site by a combination of elements dispersed throughout the locus. Development 2003, 130:3415-3426.
91. Hinits Y., Osborn D.P., Hughes S.M. Differential requirements for myogenic regulatory factors distinguish medial and lateral somitic, cranial and fin muscle fibre populations. Development 2009, 136:403-414.
92. Kucharczuk K.L., Love C.M., Dougherty N.M., Goldhamer D.J. Fine-scale transgenic mapping of the MyoD core enhancer: MyoD is regulated by distinct but overlapping mechanisms in myotomal and non-myotomal muscle lineages. Development 1999, 126:1957-1965.
93. Summerbell D., Ashby P.R., Coutelle O., Cox D., Yee S., Rigby P.W.J. The expression of Myf5 in the developing mouse embryo is controlled by discrete and dispersed enhancers specific for particular populations of skeletal muscle precursors. Development 2000, 127:3745-3757.
94. Sato T., Rocancourt D., Marques L., Thorsteinsdottir S., Buckingham M. A Pax3/Dmrt2/Myf5 regulatory cascade functions at the onset of myogenesis. PLoS Genet 2010, 6:e1000897.
95. Biressi S., Molinaro M., Cossu G. Cellular heterogeneity during vertebrate skeletal muscle development. Dev Biol 2007, 308:281-293.
96. Rudnicki M.A., Schnegelsberg P.N.J., Stead R.H., Braun T., Arnold H.-H., Jaenisch R. MyoD or Myf-5 is required for the formation of skeletal muscle. Cell 1993, 75:1351-1359.
97. Kassar-Duchossoy L., Gayraud-Morel B., Gomes D., et al. Mrf4 determines skeletal muscle identify in Myf5:Myod double-mutant mice. Nature 2004, 431:466-471.
98. Gray's anatomy 2008, Elsevier, London, p. 744. 40th ed. S. Standring (Ed.).
99. Eger K., Jordan B., Habermann S., Zierz S. Beevor's sign in facioscapulohumeral muscular dystrophy: an old sign with new implications. J Neurol 2010, 257:436-438.
100. Smogorzewska A., de Lange T. Regulation of telomerase by telomeric proteins. Annu Rev Biochem 2004, 73:177-208.
101. Arneric M., Lingner L. Tel1 kinase and subtelomere-bound Tbf1 mediate preferential elongation of short telomeres by telomerase in yeast. EMBO Reports 2007, 8:1080-1085.
102. Ng L.J., Cropley J.E., Pickett H.A., Reddel R.R., Suter C.M. Telomerase activity is associated with an increase in DNA methylation at the proximal subtelomere and a reduction in telomeric transcription. Nucleic Acid Res 2009, 37:1152-1159.
103. Park J.I., Venteicher A.S., Hong J.Y., et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 2009, 460:66-72.
104. Choi J., Southworth L.K., Sarin K.Y., et al. TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. PLoS 2008, 4:124-138.
105. O'Connor S., Carlson M., Conboy I.M. Differentiation rather than aging of muscle cells abolishes their telomerase activity. Biotechnol Prog 2009, 25:1130-1137.
106. Decary S., Hamida C.B., Mouly V., Barbet J.P., Hentati F., Butler-Browne G.S. Shorter telomeres in dystrophic muscle consistent with extensive regeneration in young children. Neuromuscul Disord 2000, 10:113-120.
107. Benetti R., Garcia-Cao M., Blasco M.A. Telomere length regulates the epigenetic status of mammalian telomeres and subtelomeres. Nat Genet 2007, 39:243-250.
108. Zeng W., de Greef J.C., Chen Y.-Y., et al. Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). PLoS Genet 2009, 5:e1000559.
109. Kagey M.H., Newman J.J., Bilodeau S., et al. Mediator and cohesin connect gene expression and chromatin architecture. Nature 2010, 467:430-435.
110. Barakat M.R., Traboulsi E.I., Sears J.E. Coats' disease, megalopapilla and Cornelia de Lange syndrome. Ophthalmic Genet 2009, 30:106-108.
111. Folk J.C., Genovese F.N., Biglan A.W. Coats' Disease in a patient with Cornelia de Lange syndrome. Am J Ophthalmal 1981, 91:607-610.
112. Sacco A., Doyonnas R., Kraft P., Vitorovic S., Blau H.M. Self-renewal and expansion of single transplanted muscle stem cells. Nature 2008, 456:502-506.
113. Smythe G.M., Grounds M.D. Exposure to tissue culture conditions can adversely affect myoblast behavior in vivo in whole muscle grafts: implications for myoblast transfer therapy. Cell Transplant 2000, 9:379-393.
114. Collins C.A., Olsen I., Zammit P.S., et al. Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell 2005, 122:289-301.
115. Christov C., Chretien F., Abou-Khalil R., et al. Muscle satellite cells and endothelial cells: close neighbors and privileged partners. Mol Biol Cell 2007, 18:1397-1409.
116. Morrison S.J., Spradling A.C. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell 2008, 132:598-611.
117. Cossu G., Molinaro M. Cell heterogeneity in the myogenic lineage. Curr Top Dev Biol 1987, 23:185-208.
118. Zammit P.S. All muscle satellite cells are equal, but are some more equal than others?. J Cell Sci 2008, 121:2975-2982.
119. Harris A.J., Duxson M.J., Fitzsimons R.B., Rieger F. Myonuclear birthdates distinguish the origins of primary and secondary myotubes in embryonic mammalian skeletal muscles. Development 1989, 107:771-784.
120. Dellavalle A., Sampaolesi M., Tonlorenzi R., et al. Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat Cell Biol 2007, 9:255-267.
121. Rey J.-P., Ellies D.L. Wnt modulators in the biotech pipeline. Dev Dyn 2010, 239:102-114.